Related Experiment Video
Updated: Jan 30, 2026
06:05
The Participant-Reported Implementation Update and Score PRIUS: A Novel Method for Capturing Implementation-Related Data Over Time
Published on: February 19, 2021
1.8K
[Gastroenterology and hepatology update 2018]
Kostantinos Gkouvatsos1, Fabrizia D'Angelo1, Stefano Guglielmi1
1Service de gastroentérologie et hépatologie, HUG, 1211 Genève 14.
Revue Medicale Suisse
|January 11, 2019
Summary
Gastroenterology novelties for 2018 include advanced hepatocellular carcinoma monitoring, new treatments for inflammatory bowel diseases like stem cell therapy and tofacitinib for ulcerative colitis, and updated criteria for eosinophilic esophagitis.
Area of Science:
- Gastroenterology
- Hepatology
- Inflammatory Bowel Disease
Background:
- Significant advancements in gastroenterology occurred in 2018.
- Key areas include hepatology, intestinal inflammatory diseases, and esophageal conditions.
Purpose of the Study:
- To summarize major gastroenterology novelties from 2018.
- To provide an update on diagnostic criteria and therapeutic advancements.
Main Methods:
- Review of recent literature and European Commission approvals.
- Focus on advancements in hepatology, inflammatory bowel disease, and esophageal disorders.
Main Results:
- Hepatology: Updates on hepatocellular carcinoma monitoring, Baveno VI criteria for esophageal varices, and cirrhotic cramps management.
- Intestinal Inflammatory Diseases: European Commission approval of stem cell therapy for perianal fistulas and tofacitinib for ulcerative colitis (RCH).
- Esophageal Conditions: Revised diagnostic criteria for eosinophilic esophagitis and a new therapy for primitive biliary cirrhosis.
Conclusions:
- 2018 brought significant therapeutic and diagnostic progress in gastroenterology.
- Novel treatments and updated criteria offer improved patient management strategies.
